Stockholders' Deficit (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jul. 24, 2019 |
Jul. 19, 2019 |
Jun. 24, 2019 |
May 31, 2019 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Aug. 31, 2019 |
Jul. 02, 2019 |
Jun. 30, 2019 |
Dec. 09, 2014 |
|
| Reverse stock split | one-for-five hundred (1:500) | one-for-five hundred (1:500) | ||||||||
| Common stock, shares authorized | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | ||||||
| Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | ||||||
| Preferred stock, shares authorized | 1,500,005 | 1,500,005 | 500,000 | |||||||
| Preferred stock, par value | $ 0.01 | $ 0.01 | ||||||||
| Common stock issued during period | 20,000 | 181,939 | ||||||||
| Conversion Price | $ 0.704 | $ 0.4725 | ||||||||
| Conversion Price, Increase | 0.906 | |||||||||
| Conversion Price, Decrease | $ 0.45 | |||||||||
| Convertible note issued during the period | $ 123,713 | $ 1,413,318 | ||||||||
| Common stock reserved for future issuances | 20,500,465 | |||||||||
| Share issued price per share | $ 1.99 | |||||||||
| Proceeds from issuance of common stock | $ 39,800 | |||||||||
| Consulting expenses | $ 39,800 | |||||||||
| Number of restricted shares issued | 78,000 | |||||||||
| Share Based Compensation | $ 114,904 | |||||||||
| Share-based Payment Arrangement, Option [Member] | ||||||||||
| Granted exercise price | $ 76.37 | |||||||||
| Share Based Compensation | $ 20,718 | |||||||||
| Grant options to purchase | 59,644 | |||||||||
| Exercise price | $ 4.65 | |||||||||
| Risk free rate | 2.42% | |||||||||
| Fair value term | 10 years | |||||||||
| Expected volatility | 268.00% | |||||||||
| Option granted value | $ 248,620 | |||||||||
| Unvested stock option recongized | $ 217,542 | |||||||||
| Warrant [Member] | ||||||||||
| Warrants to purchase common stock | 450,000 | |||||||||
| Warrant exercise price | $ 2.25 | |||||||||
| Warrants outstanding and exercisable | 975,059 | |||||||||
| Warrants expiration term description | As of September 30, 2019, there were 975,059 warrants outstanding and exercisable with expiration dates commencing May 2020 and continuing through August 2024, with a weighted average exercise price per share of $3.39. | |||||||||
| Warrants Two [Member] | ||||||||||
| Warrants to purchase common stock | 300,000 | |||||||||
| Warrant exercise price | $ 3.33 | |||||||||
| Warrants Three [Member] | ||||||||||
| Warrants to purchase common stock | 225,000 | |||||||||
| Warrant exercise price | $ 4.50 | |||||||||
| Restricted Stock Units (RSUs) [Member] | ||||||||||
| Number of restricted shares issued | 117,000 | |||||||||
| Granted exercise price | $ 4.25 | |||||||||
| Share based compensation arrangement by share based payment award options grant date fair value | $ 497,240 | |||||||||
| Share Based Compensation | $ 54,386 | |||||||||
| Unrecognized restricted stock units expense | $ 411,777 | |||||||||
| Chief Executive Officer [Member] | ||||||||||
| Common stock issued during period | 58,500 | |||||||||
| Number of restricted shares issued | 39,000 | |||||||||
| Option Description | The total 58,500 options have a term of 10 years from the date of grant and exercise price ranging from $4.25 to $4.675 per share. 1/3rd of these options shall vest every successive one-year anniversary, provided, that on each such vesting date, the Chief Executive Officer and Chief Scientific Officer are employed by the Company and subject to the other provisions of the employment agreement. The 58,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $248,620. | |||||||||
| Chief Executive Officer [Member] | Share-based Payment Arrangement, Option [Member] | ||||||||||
| Grant options to purchase | 39,000 | |||||||||
| Chief Scientific Officer [Member] | Share-based Payment Arrangement, Option [Member] | ||||||||||
| Grant options to purchase | 19,500 | |||||||||
| Series A Preferred Stock [Member] | ||||||||||
| Preferred stock, shares authorized | 500,000 | |||||||||
| Preferred stock, par value | $ 0.01 | $ 0.01 | ||||||||
| Preferred stock, shares issued | 500,000 | 500,000 | ||||||||
| Preferred stock, shares outstanding | 500,000 | 500,000 | ||||||||
| Convertible note issued during the period | ||||||||||